LQDA
Liquidia Technologies Inc
Halal Rating :
Last Price
$12.92
Last updated:
Market Cap
-
7D Change
9.86%
1 Year Change
-0.84%
Company Overview
Industries
Exchange
Next Earnings Date
Liquidia Technologies Inc is a biopharmaceutical company focused on the development and commercialization of products to treat pulmonary hypertension and other serious diseases. The company utilizes its proprietary PRINT® technology platform to develop drug therapies. Their lead product candidates include YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH).
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $4.45m | $29.42m | - | $-4219000.0 | 0.00% | 14.34% |
| June 30, 2024 | $3.66m | $33.46m | - | $2.6m | 0.00% | 7.77% |
| March 31, 2024 | $2.97m | $45.78m | - | $14.01m | 0.00% | 30.60% |
Company Impact
Help us evaluate Liquidia Technologies Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.